Rafael Holdings, Inc.
Rafael Holdings, Inc. (NYSE: RFL) is a biotechnology company that develops pharmaceuticals and holds interests in clinical- and early-stage companies developing pharmaceuticals and medical devices. Its primary focus is Trappsol® Cyclo™, an investigational intravenous therapy for Niemann-Pick Disease Type C; the… From the company’s description.
In fiscal 2026, Rafael Holdings, Inc. reported revenue of $0.87M, down 4.7% from fiscal 2025, and a net loss of $27.95M. Operations used $29.99M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Rafael Holdings, Inc. does
In the company’s own words
Rafael Holdings, Inc. (NYSE: RFL) is a biotechnology company that develops pharmaceuticals and holds interests in clinical- and early-stage companies developing pharmaceuticals and medical devices. Its primary focus is Trappsol® Cyclo™, an investigational intravenous therapy for Niemann-Pick Disease Type C; the company submitted a New Drug Application to the FDA in October 2026 after completing a Phase 3 trial. Its portfolio includes LipoMedix, developing the liposome-delivered cancer candidate Promitil®; Cornerstone Pharmaceuticals, focused on cancer metabolism therapies; and Rafael Medical Devices, whose FDA-cleared VECTR System is used in minimally invasive ligament or fascia release surgeries. Barer holds interests in early-stage cancer assets, while Day Three Labs develops technology to increase the bioavailability of third-party products. Cyclo also sells cyclodextrins and related products to pharmaceutical, nutritional and other industries. Rafael retains a portion of a commercial building in Jerusalem as its sole real estate asset. Its website is www.rafaelholdings.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEWARK, NJ
- Fiscal year end
- July
- CIK
- 1713863
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rafael Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rafael Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rafael Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rafael Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rafael Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”